A Phase 2 Study to Evaluate the Safety and Tolerability of PBI-4050 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, open-label, single-arm study of the safety and tolerability of PBI-4050
800 mg daily oral administration in 40 adult patients with IPF.
Phase:
Phase 2
Details
Lead Sponsor:
Liminal BioSciences Ltd. ProMetic BioSciences Inc.